NCT06031233View on ClinicalTrials.gov

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

PHASE4RecruitingINTERVENTIONAL
Enrollment

679

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
OncologyInfusion Reaction
Interventions
DRUG

Nivolumab

Gradual shortening of infusion times

DRUG

Pembrolizumab

Gradual shortening of infusion times

DRUG

Ipilimumab

Gradual shortening of infusion times

DRUG

Durvalumab

Gradual shortening of infusion times

DRUG

Atezolizumab

Gradual shortening of infusion times

DRUG

Bevacizumab

Gradual shortening of infusion times

DRUG

Trastuzumab

Gradual shortening of infusion times

Trial Locations (1)

8025AB

RECRUITING

Isala Hospital, Zwolle

All Listed Sponsors
lead

Isala

OTHER